NOUS 209
Alternative Names: GAd20-209-FSP; MVA-209-FSP; NOUS-209Latest Information Update: 27 Jan 2026
At a glance
- Originator Nouscom
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Oncolytic viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hereditary nonpolyposis colorectal cancer; Solid tumours
Most Recent Events
- 16 Jan 2026 Adverse events and immunogenicity data from a phase-Ib/II trial in Hereditary nonpolyposis colorectal cancer (Prevention) released by Nouscom
- 07 Nov 2025 Adverse events and immunogenicity data from phase Ib/II trial in Hereditary nonpolyposis colorectal cancer released by Nouscom
- 17 Oct 2025 Pharmacodynamics, efficacy and adverse events data from phase I/II trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)